4,291 trials (keyword fallback)
Pre-Exposure Prophylaxis · Sexually Transmitted Diseases, Bacterial · HIV Infections
Primary: Visits With PrEP Dispensation to Female Study Participants Reporting Sexual Behaviors or STI Symptoms — 211 Visits
HIV · STI
Primary: Number of Men Who Discontinue Daily Oral PrEP — 18 Participants
HIV/AIDS
Primary: PrEP Uptake at Week 1 — 63 Participants
HIV Infections · Pregnancy Related
Primary: Maternal HIV Incidence — 0.38; 0.31 incidence/100 Person years
HIV Prevention
Primary: Number of Participants Initiating PrEP — 1; 6 Participants — p=<0.05
HIV Prevention
Primary: cRCT: PrEP Initiation — 41; 41 Participants
HIV-infection/AIDS
Primary: Intervention Feasibility: Enrollment Rates Among Eligible Patients Screened — 67; 60; 27; 37 Participants
HIV/AIDS
Primary: PrEP Adherence — 12; 4 Participants
Psychotic Disorders · Mood Disorders · Stress Disorders, Post-Traumatic
Primary: Reproductive Life Goal Behavioral Intentions — 3.6; 2.7; 3.3; 3.0 score on scale
Breast Cancer · Hot Flashes · Sexual Dysfunction
Primary: Number of Participants With a 50% Decrease in Hot Flash Score — 50; 53 Participants
HIV Prevention · Transgender Health
Primary: Tenofovir Diphosphate Concentration in Dried Blood Spots (DBS) — 973.5; 1078 fmol/punch
HIV Infections · Sexually Transmitted Diseases
Primary: Feasibility of Intervention Implementation — 4.28 Scores on a scale
Human Immunodeficiency Virus Transmission · Sexually Transmitted Diseases
Primary: PrEP Prescriptions (As Measured by Chart Review) — 1; 0 Participants — p=0.51
Hiv
Primary: PrEP Retention — 100 participants
HIV Infections
Primary: Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs — 4.37; 4.27 Scores on a scale